Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $11.50.

Several equities analysts have commented on the stock. Guggenheim upped their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. BTIG Research lifted their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Needham & Company LLC upped their price target on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Morgan Stanley cut their price objective on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, March 5th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd raised its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Personalis during the 4th quarter worth $31,000. Legal & General Group Plc acquired a new position in shares of Personalis during the 2nd quarter worth $30,000. BNP Paribas Financial Markets lifted its position in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Finally, Farther Finance Advisors LLC bought a new stake in shares of Personalis during the 3rd quarter worth $66,000. 61.91% of the stock is owned by institutional investors.

Personalis Stock Performance

Shares of PSNL stock opened at $6.58 on Friday. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50. The firm’s fifty day moving average price is $8.11 and its two-hundred day moving average price is $8.39. The firm has a market capitalization of $688.48 million, a P/E ratio of -7.23 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. The company had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. As a group, equities research analysts forecast that Personalis will post -1.4 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.